Absci Enters Multi-Program Collaboration with Emerging Biotech Partner
July 07, 2022 07:05 ET
|
ABSCI Corporation
VANCOUVER, Wash. and NEW YORK, July 07, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand...
Absci Reports First Quarter 2022 Financial and Operating Results
May 11, 2022 08:00 ET
|
Absci Corp
VANCOUVER, Wash., May 11, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic...
Absci to Participate in the BofA Securities 2022 Healthcare Conference
April 28, 2022 07:00 ET
|
Absci Corp
VANCOUVER, Wash., April 28, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the...
Absci Expands Drug Discovery Capabilities with Opening of Absci AI Research Lab in New York City
April 20, 2022 07:00 ET
|
Absci Corp
VANCOUVER, Wash. and NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand...
Absci Reports Full Year 2021 Financial and Operating Results
March 22, 2022 16:05 ET
|
Absci Corp
VANCOUVER, Wash., March 22, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the...
Absci Develops Groundbreaking Machine Learning Models for In-Silico Antibody Design, Powered by NVIDIA
March 22, 2022 13:00 ET
|
Absci Corp
Absci to present in-silico drug discovery technology at NVIDIA GTC Breakthrough ML achievements highlight the viability of the computational lead optimization pipeline Absci collaborates with NVIDIA...
Absci Appoints Dr. Andreas Busch to Board of Directors
March 21, 2022 16:05 ET
|
Absci Corp
VANCOUVER, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the...
Absci to Present at Global AI Conference NVIDIA GTC
March 16, 2022 08:00 ET
|
Absci Corp
VANCOUVER, Wash., March 16, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a drug and target discovery company harnessing deep learning, AI and synthetic biology to expand the...
Absci to Participate on Synthetic Biology Enabling Drug Discovery Panel at Cowen 42nd Annual Health Care Conference
March 01, 2022 08:00 ET
|
Absci Corp
VANCOUVER, Wash., March 01, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the...
Absci to Participate in Upcoming Investor Conferences
February 17, 2022 08:00 ET
|
Absci Corp
VANCOUVER, Wash., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the...